Navigating the evolving landscape for psychedelic therapies
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA combines in-depth industry knowledge and cutting-edge analytics to evaluate issues being litigated and debated in the healthcare sector. Our industry knowledge enables us to explain, for example, the nuances of provider reimbursement or the patient incentives created by high deductible health insurance plans, and our economic, statistical, accounting, investigative, and finance skills—as well as our familiarity with key healthcare datasets—equips CRA to provide rigorous, defensible analyses tailored to the specific facts of a litigation or regulatory dispute.
Our experts have broad and deep experience in the healthcare sector including hospitals, physician practices, health insurance and health benefit plans, ACOs, PBMs, wholesalers, pharmacies, pharmaceuticals and biologicals, medical devices, clinical laboratories, dialysis facilities, ambulance transport, nursing homes, and home healthcare.
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...
A variety of contraceptive options exist, each with their own pros and cons. Long-acting reversible contraceptives (LARCs), like IUDs, contraceptive...
CRA is a proud sponsor of the event. Elina Koustoumpardi is a speaker during the presentation titled “EU Commission Revision of 102 Guidelines: Impact on...
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...